NCT04058145 is a Phase 2 clinical trial of AMD3100 in Head and Neck Cancer, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT04058145?

NCT04058145 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT04058145?

Interventions in NCT04058145: AMD3100, Pembrolizumab.

What condition does NCT04058145 study?

NCT04058145 studies Head and Neck Cancer.

Is NCT04058145 still recruiting?

NCT04058145 is currently withdrawn. Last updated 7 September 2020.

Last reviewed 2020-09-07 · How we verify

NCT04058145

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma

Withdrawn Phase 2 Last updated 7 September 2020

What this trial tests

Phase 2 trial testing AMD3100 in Head and Neck Cancer. Withdrawn.

Timeline

30 September 2019

Primary endpoint
11 October 2019

11 October 2019

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	30 September 2019
Primary completion	11 October 2019
Estimated completion	11 October 2019
Sites	2 locations across United States

Drugs / interventions tested

AMD3100 — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

Head and Neck Cancer — all drugs for Head and Neck Cancer →

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research is studying the safety and effectiveness of AMD3100 and pembrolizumab in participants with metastatic head and neck squamous cell carcinoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting tumor-associated macrophages to synergize tumor immunotherapy.
Xiang X, Wang J, Lu D, Xu X. · · 2021 · cited 712× · PMID 33619259 · DOI 10.1038/s41392-021-00484-9
The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment.
Kim SK, Cho SW. · · 2022 · cited 300× · PMID 35685630 · DOI 10.3389/fphar.2022.868695
Targeting cytokine and chemokine signaling pathways for cancer therapy.
Yi M, Li T, Niu M, Zhang H, et al · · 2024 · cited 264× · PMID 39034318 · DOI 10.1038/s41392-024-01868-3
Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses.
Anfray C, Ummarino A, Andón FT, Allavena P. · · 2019 · cited 222× · PMID 31878087 · DOI 10.3390/cells9010046
Cancer-Associated Fibroblasts: Understanding Their Heterogeneity.
Louault K, Li RR, DeClerck YA. · · 2020 · cited 117× · PMID 33114328 · DOI 10.3390/cancers12113108
Neutrophils in the era of immune checkpoint blockade.
Faget J, Peters S, Quantin X, Meylan E, et al · · 2021 · cited 94× · PMID 34301813 · DOI 10.1136/jitc-2020-002242
Research trends in pharmacological modulation of tumor-associated macrophages.
Wang N, Wang S, Wang X, Zheng Y, et al · · 2021 · cited 88× · PMID 33463063 · DOI 10.1002/ctm2.288
Targeting of TAMs: can we be more clever than cancer cells?
Kzhyshkowska J, Shen J, Larionova I. · · 2024 · cited 79× · PMID 39516356 · DOI 10.1038/s41423-024-01232-z

Verify or expand the search:

Other trials of AMD3100

Trials testing the same drug.

NCT04045821 — Endometrial Rejuvenation Study · NA · terminated
NCT00322127 — An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers · Phase 1 · completed

Other recruiting trials for Head and Neck Cancer

Currently open trials in the same condition.

NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04058145 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 7 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04058145.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing